1. Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy 
Nicoletta Colombo, Martin Gore 
Critical Reviews in Oncology / Hematology 
Volume 64, Issue 2, Pages (November 2007)
DOI: /j.critrevonc
Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1
Kaplan–Meier survival curves for (a) patients with a platinum-free interval >6 months and (b) for patients with a platinum-free interval of 6–12 months (partially platinum-sensitive disease) treated with pegylated liposomal doxorubicin (PLD) vs. topotecan demonstrate that the survival benefit was more prominent in partially platinum-sensitive patients treated with PLD. (a) HR=1.43 (95% CI: 1.01, 1.92) in 219 patients (with permission from Ref. [17]). (b) HR=1.58 (95% CI: 1.07, 2.34) in 122 patients (Personal communication, Alan N. Gordon, Dallas, Texas).
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
Schema for the Gynecologic Cancer Intergroup phase III CALYPSO study.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions

4. Fig. 3
Schema for the phase III Gynecologic Oncology Group (GOG) 213 study evaluating combination vs. sequential chemotherapy for the treatment of platinum-sensitive ROC.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2007 Elsevier Ireland Ltd Terms and Conditions